Effectiveness and Safety of Telmisartan-Amlodipine Fixed-Dose Combination in Indian Hypertensive Patients with Type 2 Diabetes: A Subgroup Analysis from the TACT India Real-World Study

Presenter: A. Sugumaran

This subgroup analysis from the TACT India study evaluated the safety and efficacy of telmisartan/amlodipine fixed-dose combination (T/A FDC) in Indian hypertensive patients with type 2 diabetes mellitus (T2DM). 

Among 5363 participants, 72.11% had T2DM. The treatment led to significant reductions in systolic (−19.11 mmHg) and diastolic (−16.05 mmHg) blood pressure over 8 weeks (both P<0.001). Adverse events were minimal and mild. More than 98% of physicians and 99% of patients reported satisfaction with the therapy. These findings support T/A FDC as a well-tolerated and efficacious option for patients with T2DM, addressing shared risk factors like insulin resistance and obesity.

Silent Hypertension in Newly Diagnosed Type 2 Diabetes: Age Dependent Prevalence and Cardiovascular Risk Implications

Presenter: S. S. Patil

This study explores the prevalence and severity of undiagnosed hypertension in newly diagnosed type 2 diabetes mellitus (T2DM) patients across age groups. 

In a cross-sectional analysis of 591 individuals, prevalence of undiagnosed hypertension was significantly age-dependent being the most common in older adults (50%) than in middle-aged (23%) and young adults (11.2%). Mean systolic blood pressure and grade 1 hypertension increased with age. Older adults also showed higher rates of obesity and dyslipidemia, indicating compounded cardiovascular risk. The strikingly high prevalence of ‘silent hypertension’ highlights the importance of comprehensive cardiovascular risk assessment at the diagnosis of diabetes especially in older adults. 

Long-Term Incidence and Case-Fatality Rates of Myocardial Infarction in People with Newly Diagnosed Diabetes and Impaired Glucose Tolerance: The Da Qing Diabetes 34-Year Follow-Up

Presenter: J. Xu

In a 34-year follow up cohort study of 1,632 adults in Da Qing, China, myocardial infarction (MI) incidence and case-fatality rates (CFR) were evaluated across groups with newly diagnosed diabetes (NDD), impaired glucose tolerance (IGT), and normal glucose tolerance (NGT). 

After adjusting for key risk factors, NDD had significantly elevated MI risk (HR: 3.54), IGT non-intervention group (HR: 2.34) and intervention group (HR: 1.86) compared to NGT. Compared to NDD, those with IGT who received a 6-year lifestyle intervention had a significantly lower risk of MI (HR: 0.56), while the non-intervention IGT group showed no significant difference (HR: 0.68). CFR for MI was significantly elevated in NDD (HR: 1.62) and trended higher in IGT without intervention (HR: 1.50), whereas IGT with intervention showed reduced mortality risk (HR: 0.83). Early lifestyle intervention in IGT effectively lowered MI incidence and mortality.

EASD 2025, 15th – 19th Sept 2025, Vienna, Austria.